These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 15246889)

  • 1. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus.
    Sidhu JS; Cowan D; Kaski JC
    Am J Cardiol; 2004 Jul; 94(2):151-6. PubMed ID: 15246889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome.
    Wang TD; Chen WJ; Cheng WC; Lin JW; Chen MF; Lee YT
    Am J Cardiol; 2006 Oct; 98(8):1057-62. PubMed ID: 17027571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.
    Caballero AE; Saouaf R; Lim SC; Hamdy O; Abou-Elenin K; O'Connor C; Logerfo FW; Horton ES; Veves A
    Metabolism; 2003 Feb; 52(2):173-80. PubMed ID: 12601628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aged garlic extract improves endothelial function in men with coronary artery disease.
    Williams MJ; Sutherland WH; McCormick MP; Yeoman DJ; de Jong SA
    Phytother Res; 2005 Apr; 19(4):314-9. PubMed ID: 16041725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
    De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
    J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease.
    Sidhu JS; Cowan D; Tooze JA; Kaski JC
    Am Heart J; 2004 Jun; 147(6):e25. PubMed ID: 15199366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease.
    Settergren M; Böhm F; Rydén L; Pernow J
    Eur Heart J; 2008 Jul; 29(14):1753-60. PubMed ID: 18441323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.
    Kovacic JC; Martin A; Carey D; Wand H; Mallon PW; Feneley MP; Emery S; Cooper DA; Carr A;
    Antivir Ther; 2005; 10(1):135-43. PubMed ID: 15751771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Esposito K; Ciotola M; Carleo D; Schisano B; Saccomanno F; Sasso FC; Cozzolino D; Assaloni R; Merante D; Ceriello A; Giugliano D
    Diabetes Care; 2006 May; 29(5):1071-6. PubMed ID: 16644639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial function and biochemical vascular markers in first-degree relatives of type 2 diabetic patients: the effect of exercise training.
    Ostergård T; Nyholm B; Hansen TK; Rasmussen LM; Ingerslev J; Sørensen KE; Bøtker HE; Saltin B; Schmitz O
    Metabolism; 2006 Nov; 55(11):1508-15. PubMed ID: 17046554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes.
    Aversa A; Vitale C; Volterrani M; Fabbri A; Spera G; Fini M; Rosano GM
    Diabet Med; 2008 Jan; 25(1):37-44. PubMed ID: 18199130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients.
    Sidhu JS; Cowan D; Kaski JC
    J Am Coll Cardiol; 2003 Nov; 42(10):1757-63. PubMed ID: 14642684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus.
    Wang CH; Ting MK; Verma S; Kuo LT; Yang NI; Hsieh IC; Wang SY; Hung A; Cherng WJ
    Am Heart J; 2006 Dec; 152(6):1051.e1-8. PubMed ID: 17161050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.
    Wang TD; Chen WJ; Lin JW; Chen MF; Lee YT
    Am J Cardiol; 2004 Feb; 93(3):362-5. PubMed ID: 14759393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired vascular function during short-term poor glycaemic control in Type 1 diabetic patients.
    Sørensen VR; Mathiesen ER; Clausen P; Flyvbjerg A; Feldt-Rasmussen B
    Diabet Med; 2005 Jul; 22(7):871-6. PubMed ID: 15975101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular, metabolic, and inflammatory abnormalities in normoglycemic offspring of patients with type 2 diabetes mellitus.
    Tesauro M; Rizza S; Iantorno M; Campia U; Cardillo C; Lauro D; Leo R; Turriziani M; Cocciolillo GC; Fusco A; Panza JA; Scuteri A; Federici M; Lauro R; Quon MJ
    Metabolism; 2007 Mar; 56(3):413-9. PubMed ID: 17292732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artichoke juice improves endothelial function in hyperlipemia.
    Lupattelli G; Marchesi S; Lombardini R; Roscini AR; Trinca F; Gemelli F; Vaudo G; Mannarino E
    Life Sci; 2004 Dec; 76(7):775-82. PubMed ID: 15581909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty.
    Wang G; Wei J; Guan Y; Jin N; Mao J; Wang X
    Metabolism; 2005 May; 54(5):590-7. PubMed ID: 15877288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity.
    Rudofsky G; Reismann P; Grafe IA; Konrade I; Djuric Z; Tafel J; Buchbinder S; Zorn M; Humpert PM; Hamann A; Morcos M; Nawroth PP; Bierhaus A
    Horm Metab Res; 2007 Sep; 39(9):665-71. PubMed ID: 17846974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.